Asthma as worldwide problem of all countries has highly direct and indirect costs, and also, mortality, morbidity and health system involvement are main problems of asthma. On the other hand, allergic rhinitis as nasal and upper airways inflammation can reduce quality of life, especially in children. Therefore, controlling of the rhinitis and asthma attack is the main goal of asthma treatment (1, 4). Asthma is a complex inflammatory airways disease, which characterized by eosinophilic infiltration, mucus hyper-secretion, goblet cell hyper-plasia, airway hyper-responsiveness and reversible airflow obstruction and allergy comprises the main causes of asthma (2, 3). In our study, there was no significant difference between treated and non-treated asthma and rhinitis groups. May be crotonic acid has weakly effect on the allergopathology mediators.
Airway inflammation heterogeneity in asthma indicates there are different mechanisms involved. Inflammation, allergic reaction, and immune response dysregulation are main mechanisms. The main symptoms of asthma are mucus over secretion, bronchoconstriction, and airway inflammation that lead to cough, airways obstruction, wheezing, breathlessness, and chest tightness (2, 4). Crotonic acid was employed to the immunomycin production by Streptomyces hygroscopicus var. ascomyceticus as immunosuppressant agent (9). N-(trifluoromethylphenyl)-2-cyano-3-hydroxy-crotonic acid amide (A77 1726) has anti-proliferative effects and anti-inflammatory actions in animal models. Also, in psoriasis clinical trials, it has effect on the epidermal hyperproliferation and inflammatory cells infiltration (10, 11). Goblet cell hyperplasia, perivascular and peribronchial inflammation were cotrolled by crotonic treatment in asthmatic mice. Also, perivascular inflammation was controlled in A.Cro.Glu group better than A.cro group and showed that when crotonic acid was used with gluconic acid, it can have strong effect in control of inflammation. However, it had anti-proliferative and anti-hyperplasia effect on the goblet cells that is important in asthmatic patients.
Environmental triggers in genetically predisposed peoples activate Th2 immune response and orchestrate asthma pathophysiology. Some infections such as Linguatula serrata can change expression of some related molecules and immune responses that should be noted (12, 13). IL-13 plays important role in the mucus secretion and goblet cell hyperplasia. IL-5 activates eosinophils and migration to airways (bronchial inflammation). IL-4 induces IgE isotype switching and mast cells activation. IL-4, IL-5, and IL-13 are increased in the asthmatic patients (1, 3, 4). The g-Aminobutyric acid (GABA) receptors express in granule cells and its agonist cis-4-amino-crotonic acid evokes currents in granule cells (14). Honaucin A consists of 4-chlorocrotonic acid and (S)-3-hydroxy-g-butyrolactone that are connected via an ester linkage and can inhibit lipopolysaccharide-stimulated nitric oxide production. The nitric oxide decreasing is accompanied by transcription decreasing of several pro-inflammatory cytokines. It can be applied in therapeutic areas that are related with inflammation, such as asthma (15, 16). On the other side, cell signaling pathways are important targets for the asthma treatment and recognition of the new ligands (agonists or antagonists) for adaptor molecules can provide new therapeutic approach (1, 3). Crotonic acid may have targeted effect on the cell signaling and may control signaling pathways that are related in inflammation, cell migration and cell proliferation.
This should be considered that development of new anti-inflammatory therapies that target cyclooxygenases (COX) 1 and 2 in patients with allergic diseases are necessary. The crotonic acid agents can be new modulators of inflammation (17, 18). However, some metabolits can attenuate the immune response by inhibition of the transcriptional activity of peroxisome-proliferator-activated receptor gamma (PPARg) and may be explain role in immunomodulation and anti-inflammatory effects (19–21). In this study, the level of IL-5 was decreased in asthma and allergic rhinitis groups that were treated with crotonic acid and also crotonic with gluconic acid. IL-5 level was decreased significantly in A.Cro.Glu group compared with A.Cro group that was showed that when crotonic acid was used with gluconic acid, it had powerful effect in control of IL-5 releasing. May be gluconic acid had protective effect on crotonic acid in the airway and leaded to increasing of stability and efficacy of crotonic acid. Crotonic acid can control inflammation (especially eosinophilic inflammation) via harnessing of IL-5 around bronchial and vessels and also prevent goblet cell proliferation and hyperplasia. When it was used with gluconic acid, had strong effect on control of allergic rhinis and asthma immunopathology. Our study showed that crotonic acid had anti-inflammatory and immunomodulatory effects and its effect on control of inflammation is more powerful that anti-allergy effect, even was used with gluconic acid.
Some limitations were in this study. We did not study Th1 cytokines levels and could not study airway hyperresponsiveness. Some cellular signaling pathway such as NF-κB and the MAP kinase and inflammatory factors such as COX-2, iNOS, and PGs that have effect on asthma pathophysiology, were not studied that should be noted in future researches. Also, we could not find similar study (using Crotonic acid on allergy) and could no compare our result with publicized studies.